ACUTE TOXICITY STUDY OF (Z)-1-BENZHYDRYL-4- CINNAMYLPIPERAZINES IN SWISS ALBINO MICE
Abstract
Â
Objective: The objective was to study the acute toxicity of (Z)-1-benzhydryl-4-cinnamylpiperazine derivatives (1a-c) using Swiss Albino mice.
Methods: The acute oral and dermal toxicity studies were carried out based on OECD guidelines by adopting fixed dosage method (the limit dose
is 2000 mg/kg body weight of test animal in case of dermal toxicity and 5000 mg/kg in oral toxicity). Toxicity and mortality rates were studied at
intervals of 6 hrs and 14 hrs after administration of test compounds for 14 days.
Results: (Z)-1-benzhydryl-4-cinnamyl piperazine derivatives (1a-c) at oral treatment of 5000 mg/kg BW and dermal toxicity study of 2000 mg/kg
BW did not show any pronounced toxicity indicating their potential use for therapeutic purposes.
Conclusion: All compounds 1a-c did not cause any mortality or changes in general behavior of the test animals at oral treatment of 5000 mg/kg BW
indicating no conspicuous toxicity at the highest dose administered.
Keywords: (Z)-1-benzhydryl-4-cinnamyl piperazine derivatives, Acute toxicity, Albino mice, Cinnarizine, Flunarizine.
Downloads
References
Sweetman SC. Martindle, the Complete Drug Reference. 33rd ed. London: The Pharmaceutical Press; 2002. p. 413-8.
Lee JA, Watson LA, Boothby G. Calcium antagonists in the prevention of motion sickness. Aviat Space Environ Med 1986;57(1):45-8.
Verspeelt J, De Locht P, Amery WK. Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. Eur J Clin Pharmacol 1996;51(1):15-22.
Rascol O, Clanet M, Montastruc JL. Calcium antagonists and the vestibular system: A critical review of flunarizine as an antivertigo drug. Fundam Clin Pharmacol 1989;3 Suppl:79S-87.
Mena MA, Garcia de Yébenes MJ, Tabernero C, Casarejos MJ, Pardo B, Garcia de Yébenes J. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995;18(5):410-26.
Micheli FE, Pardal MM, Giannaula R, Gatto M, Parera I, Paradiso G, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord 1989;4(2):139-46.
Lucertini M, Mirante N, Casagrande M, Trivelloni P, Lugli V. The effect of cinnarizine and cocculus indicus on simulator sickness. Physiol Behav 2007;91(1):180-90.
Van Nueten JM, Janssen PA. Comparative study of the effects of flunarizine and cinnarizine on smooth muscles and cardiac tissues. Arch Int Pharmacodyn Ther 1973;204(1):37-55.
Barber JH, Reuter CA, Jageneau AH, Loots W. Intermittent claudication: A controlled study in parallel time of the short-term and long-term effects of cinnarizine. Pharmatherapeutica 1980;2(6):401-7.
Desmedt LK, Niemegeers CJ, Janssen PA. Anticonvulsive properties of cinnarizine and flunarizine in rats and mice. Arzneimittelforschung 1975;25(9):1408-13.
Schetz J, Bostoen H, Clement D, Fornhoff M, Haerens AR, Staessen AI. Flunarizine in chronic obstructive peripheral arterial disease. A placebo-controlled, double-blind, randomized multicentre trial. Curr Ther Res Clin Exp 1978;23:121-30.
Jan M, Paul MV. Flunarizine. In: Scriabine A, editor. New Drugs Annual: Cardiovascular Drugs. Vol. 2. New York: Raven Press; 1984.
Shivaprakash S, Burman A, Dewakar L, Reddy GC. In vivo studies of (Z)-1-benzhydryl-4- cinnamylpiperazines as anti-inflammatory and analgesics. Int J Pharm 2014;4(3):154-7.
Shivaprakash S, Reddy GC. Stereoselective synthesis of (Z)-1-benzhydryl-4- cinnamylpiperazines via the Wittig reaction. Synth Commun 2014;44:600-9.
OECD Guidelines for the Testing of Chemicals (No. 423) Acute Oral Toxicity-Acute Toxic Class Method [Adopted on 2011 Dec 17]. (b) OECD Guidelines for the Testing of Chemicals (No. 402) Acute Dermal Toxicity-Acute Toxic Class Method [Adopted on 2004 May 14]. (1st Version).
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.